Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

LAHORE: The Punjab government announced on Friday that those seeking assistance under the Nighaban Ramazan package should get themselves registered by Feb 15. It also announced that registration ...

DAVOS, Switzerland, Jan 24 (Reuters) - Saudi Economy Minister Faisal Alibrahim said on Friday that the kingdom's $600 billion expanded package with the United States includes investments as well ...